Jpmorgan Chase & CO Volitionrx LTD Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VNRX
# of Institutions
26Shares Held
17.8MCall Options Held
41KPut Options Held
100-
Armistice Capital, LLC New York, NY9MShares$6.12 Million0.09% of portfolio
-
Lagoda Investment Management, L.P. New York, NY6.1MShares$4.14 Million2.11% of portfolio
-
Geode Capital Management, LLC Boston, MA730KShares$496,7040.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA637KShares$432,9330.0% of portfolio
-
Black Rock Inc. New York, NY516KShares$350,9290.0% of portfolio
About VOLITIONRX LTD
- Ticker VNRX
- Exchange NYSE
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 57,297,000
- Market Cap $39M
- Description
- VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating sampl...